{
  "author": "Popochu",
  "the_new_excerpt": "Biogen's Aduhelm has been approved by the FDA to treat Alzheimer's Disease.\nTrading of Biogen (BIIB) is still halted as of 11:18 AM (Eastern). EDIT: Trading\nscheduled to resume at 1:30 PM (ET).\n\nAduhelm targets amyloid plaque deposits, long thought to be associated with the\ncognitive decline of…",
  "original_created_utc": 1623079204,
  "localize": [
    {
      "locale": "ja",
      "the_new_excerpt": "バイオジェン社のAduhelmがアルツハイマー病の治療薬としてFDAに承認されました。\nバイオジェン(BIIB)の取引は午前11時18分(東部)現在、まだ停止しています。EDIT：取引\nは午後1時30分（東部時間）に再開される予定です。\n\nAduhelmは、長年、認知機能の低下に関連すると考えられてきたアミロイドプラークの沈着を標的としています。\n認知機能の低下に関係していると考えられてきた...",
      "title": "バイオジェン社（BIIB）の医薬品Aduhelm（Aducanumab）がアルツハイマー型認知症治療薬としてFDAから承認を取得"
    },
    {
      "locale": "zh",
      "the_new_excerpt": "百健公司的Aduhelm已被FDA批准用于治疗阿尔茨海默病。\n截至上午11点18分（东部时间），百健公司（BIIB）的交易仍在停止。编辑：交易\n定于下午1:30（东部时间）恢复。\n\nAduhelm的目标是淀粉样斑块沉积，长期以来被认为是与\n的认知能力下降有关。",
      "title": "百健公司（BIIB）的药物Aduhelm（Aducanumab）被FDA批准用于阿尔茨海默病的治疗"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "百健公司的Aduhelm已被FDA批准用於治療阿爾茨海默病。\n截至上午11點18分（東部時間），百健公司（BIIB）的交易仍在停止。編輯：交易\n定於下午1:30（東部時間）恢復。\n\nAduhelm的目標是澱粉樣斑塊沉積，長期以來被認爲是與\n的認知能力下降有關。",
      "title": "百健公司（BIIB）的藥物Aduhelm（Aducanumab）被FDA批准用於阿爾茨海默病的治療"
    }
  ],
  "title": "Biogen (BIIB) drug Aduhelm (Aducanumab) Approved by FDA for Alzheimer's Disease Treatment",
  "created_utc": 1623130063,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><p>Biogen&#39;s Aduhelm has been approved by the FDA to treat Alzheimer&#39;s Disease.  <del>Trading of Biogen (BIIB) is still halted as of 11:18 AM (Eastern).</del>  EDIT: Trading scheduled to resume at 1:30 PM (ET).</p>\n\n<p>Aduhelm targets amyloid plaque deposits, long thought to be associated with the cognitive decline of Alzheimer&#39;s Disease.  There are still many hurdles with translating the drug to profits, as a followup study is pending.  Pricing concerns based on drug efficacy raised by the Institute for Clinical and Economic Review (ICER) may also lower the upper limit of profitability.  Insurers may be hesitant to cover Aduhelm without a clearer demonstration of efficacy.</p>\n\n<p><a href=\"https://www.streetinsider.com/Corporate+News/FDA+Announces+Approve+of+Biogens+%28BIIB%29+Treatment+for+Alzheimers+Disease/18527815.html\">https://www.streetinsider.com/Corporate+News/FDA+Announces+Approve+of+Biogens+%28BIIB%29+Treatment+for+Alzheimers+Disease/18527815.html</a></p>\n</div><!-- SC_ON -->",
  "score": 41,
  "permalink": "/r/stocks/comments/nuf3aq/biogen_biib_drug_aduhelm_aducanumab_approved_by/",
  "subreddit": "stocks",
  "id": "nuf3aq",
  "is_self": true,
  "media": null,
  "is_video": false,
  "source_updated_at": 1623404888027
}